Hello Jeremy! Thanks for your feedback. It's an interesting angle indeed, but not yet supported by NovumRNA. It works on the single-sample level to assemble the isoforms and also account for single-point variants.

👏 Congratulations to Markus Ausserhofer for leading this effort! I am extremely grateful for the amazing support we had through this journey from all our collaborators, supporting institutions, and funding agencies! @uniinnsbruck.bsky.social @fwf-at.bsky.social @erc.europa.eu @oenb.at @ec.europa.eu

These results highlight not only the value of NovumRNA for the identification of novel #immunotherapy targets, but also for the selection of drugs that can synergize with immunotherapy

👉 You can read the full paper on iScience: doi.org/10.1016/j.is...

We extensively benchmarked NovumRNA on public and newly generated datasets, confirming its accuracy

Analysis of hard-to-treat #cancers demonstrated that NovumRNA can be used to identify candidate tumor-antigen targets also in tumors with low mutational burden and to detect therapy-induced ncTSAs

Non-canonical tumor-specific antigens (ncTSAs) represent an untapped pool of targets for cancer immunotherapy, but their reliable prediction is challenging. With NovumRNA, we introduce a fully automated #Nextflow pipeline that predicts different classes of ncTSAs directly from patients’ RNA-seq data

Join us for a series of presentations from leading data science experts, including @francescafinotello.bsky.social, @dominicgrun.bsky.social, Johanna Klughammer, Malte Lücken, @fabiantheis.bsky.social and @jwrth.genomic.social.ap.brid.gy.

Thanks @itisalist.bsky.social for your great talk and for the insightful discussions. I am excited we are making our collaboration even stronger. And you should definitely come back to enjoy a sunnier scenery :)

Great idea! I am an assistant professor in #bioinformatics and group leader at the University of Innsbruck, Austria. I develop and apply computational tools to advance precision medicine and immuno-oncology 🧬🖥️🧪👩‍🔬